Hansoh Pharmaceutical Group Co (HKSE:03692) ROCE % : 18.16% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hansoh Pharmaceutical Group Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 18.16%.

Hansoh Pharmaceutical Group Co ROCE % Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co ROCE % Chart

Hansoh Pharmaceutical Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

34.64

20.25

16.10

11.17

14.16

Hansoh Pharmaceutical Group Co Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial									15.26	12.10	10.82	11.67	18.16

Hansoh Pharmaceutical Group Co ROCE % Calculation

Hansoh Pharmaceutical Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	4192.273	/	( ( (33503.54 - 2925.236)	+	(36137.447 - 7506.439) )	/ 2 )
	=	4192.273	/	( (30578.304	+	28631.008)	/ 2 )
	=	4192.273	/	29604.656
	=	14.16 %

Hansoh Pharmaceutical Group Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	5036.224	/	( ( (34937.883 - 8111.386)	+	(36137.447 - 7506.439) )	/ 2 )
	=	5036.224	/	( ( 26826.497	+	28631.008 )	/ 2 )
	=	5036.224	/	27728.7525
	=	18.16 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Hansoh Pharmaceutical Group Co (HKSE:03692) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hansoh Pharmaceutical Group Co ROCE % Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » ROCE %

Traded in Other Exchanges

3KY:Germany

Address

287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210

Website

https://www.hspharm.com

Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines